



Holista Colltech Limited
(ASX:HCT / ABN 24 094 515 992)
283 Rokeby Road Subiaco WA 6008
P: +61 412 474 180
W: www.holistaco.com

Appendix 4C and Activities Report for the Quarter ended 31 March 2026

ASX Announcement

28 April 2026

Holista Colltech Limited (ASX: HCT, “Holista” or “the Company”) is pleased to provide the following update on its operational and financial performance for the quarter ended 31 March 2026, together with the accompanying Appendix 4C.

Key Highlights

- **Revenue of approximately \$1.49 million** recorded across core segments, with continued contribution from the Supplement segment.
- **Supplement segment revenue maintained at approximately \$1.47 million** during the quarter, reflecting continued customer demand.
- **Infection Control/Agriculture segment recorded continued commercial orders**, following completion of trial activities in FY2025.
- **Prolmmune legal matter progressed to settlement** following the Supreme Court of Western Australia judgement in April 2026.

Financial Overview


The Group continued to monitor cash utilisation and operating expenditure during the quarter.

Cash receipts from customers for the quarter were approximately \$1.31 million.

Payments for operating activities were approximately \$1.47 million, reflecting stable cost levels during the quarter.

The Group recorded a net operating cash outflow for the quarter, primarily due to

- inventory build-up to support Q1 FY2026 operations, with payments for stock recognised during the quarter
- one-off legal fees of \$20,000



**FY2025 figures have been adjusted to audited figures.
FY2026 figures are subject to audit.*


Cash movements during the quarter also included:

- **Investing Activities:** Net cash outflow of \$30,000, mainly attributable to a fixed deposit placement linked to our banking facilities.
- **Financing Activities:** Net outflow of \$54,000 from scheduled debt repayments.

Divisional Performance

Group revenue totalled approximately \$1.49 million, reflecting broadly consistent performance compared to the prior quarter. Revenue contributions continued to be derived primarily from the Supplement segment.

- **Supplement Segment:**
Revenue of approximately \$1.47 million, maintained during the quarter, reflecting continued customer demand.
- **Food Ingredients Segment:**
Revenue of approximately \$11,000, representing modest contribution during the quarter.
- **Ovine Collagen Segment:**
No revenue recorded due to supply and fulfilment timing.
- **Infection Control / Agriculture Segment:**
Revenue of approximately \$13,000, reflecting continued commercial orders following trial activities in FY2025.



**FY2025 figures have been adjusted to audited figures.*

FY2026 figures are subject to audit.

Settlement of Prolmmune Legal Matter

As announced by the Company on 22 April 2026, the Group provides the following update regarding the Prolmmune legal proceedings.

On 7 April 2026, the Supreme Court of Western Australia granted summary judgement in favour of Prolmmune, allowing for the enforcement of a U.S. judgment against the Group. In response, the Group has successfully negotiated a settlement to resolve the judgement debt and all associated claims amounting to USD2.4 million.

Key Settlement Terms:

- **Total Amount:** USD1.8 million.
- **Payment Schedule:** An initial payment of USD1.0 million on 22 April 2026, with the remaining USD0.8 million balance due by 14 July 2026.
- **Finality:** Upon completion of these payments, all claims and proceedings between the parties will be fully and finally resolved.

This settlement effectively concludes the legal dispute between the Group and Prolmmune.

-ENDS-

About Holista Colltech Limited

Holista Colltech Limited (ASX: HCT) is a Perth-based innovator in health and wellness solutions. Operating across four dynamic business divisions—Dietary Supplements, Healthy Food Ingredients, Ovine Collagen, and Infection Control/Agriculture Solutions—Holista delivers cutting-edge products that blend nature and science for healthier lifestyles.

Our portfolio features leading nutritional supplements, patented low-GI food ingredients, premium disease-free ovine collagen, and eco-friendly, non-toxic sanitizers for everyday and industrial use. We are dedicated to sustainable, science-driven solutions that empower better living and create lasting value for our stakeholders worldwide.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

HOLISTA COLLTECH LIMITED (ASX: HCT)

ABN

24 094 515 992

Quarter ended ("current quarter")

31 March 2026

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
1.	Cash flows from operating activities		
1.1	Receipts from customers	1,312	1,312
1.2	Payments for:		
	(a) research and development	(5)	(5)
	(b) product manufacturing and operating costs	(1,027)	(1,027)
	(c) advertising and marketing	157	157
	(d) leased assets	-	-
	(e) staff costs	(445)	(445)
	(f) administration and corporate costs	(108)	(108)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	-	-
1.5	Interest and other costs of finance paid	(26)	(26)
1.6	Income taxes paid	(14)	(14)
1.7	Government grants and tax incentives	-	-
1.8	Other (ASIC Penalty)	-	-
1.9	Net cash from / (used in) operating activities	(155)	(155)
2.	Cash flows from investing activities		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	30	30
	(e) intellectual property	-	-
	(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
2.2	Proceeds from the disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) Investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	30	30
3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of share options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	1,474	1,474
3.6	Repayment of borrowings	(1,528)	(1,528)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	(54)	(54)
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	2,161	2,161
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(155)	(155)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	30	30
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(54)	(54)
4.5	Effect of movement in exchange rates on cash held	(38)	(38)
4.6	Cash and cash equivalents at end of period	1,944	1,944

5. Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1 Bank balances	856	1,057
5.2 Call deposits	1,088	1,104
5.3 Bank overdrafts	-	-
5.4 Other (Restricted Cash)	-	-
5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above)	1,944	2,161

6. Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1 Aggregate amount of payments to related parties and their associates included in item 1	10
6.2 Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i> Fees include Salaries, Director Fees and Consulting Fees to Executive Director and Non-Executive Directors	

7. Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1 Loan facilities	430	430
7.2 Credit standby arrangements	2,350	1,044
7.3 Other (please specify)		
7.4 Total financing facilities	2,780	1,474
7.5 Unused financing facilities available at quarter end		1,306
7.6 Include in the box below a summary of each finance facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
Summary of Banking Facilities:		
<u>Bank Loan Facility 1:</u> Parties: CIMB Islamic Bank Berhad Malaysia (Banker), and Holista Biotech Sdn Bhd (100% subsidiary of Holista Collect Ltd) (Borrower). i) Loan Facility 1 Term Loan Principal Amount: MYR 1.4M / approximately A\$506K Remaining Payable as at 31 March 2026: MYR 1.12M / approximately A\$405K Term: Commencing on 1 October 2020 and repayable over 240 monthly instalments (principal plus interest) of \$3,147 (2025: \$3,204) and ending in 200 months on 4 October 2040. Interest Rate: 3.50% per annum (2025: 3.74%). ii) Credit Standby Arrangement 1 Trade Financing and Banker Acceptances bears interest of 4.83% per annum (2025: 4.83%). Total Amount at Quarter End: MYR 2M / Approximately A\$723K Total Utilised at Quarter End: MYR 1.550K / Approximately A\$560K Bank Loan Facility 1 is secured by the following: • Fixed deposit with a licensed bank of the Group and the Company; • Facility agreement; • First party assignment over the office lots of the Company; • Deed of assignment of rental proceeds; • Executed fresh letter of authorisation, memorandum of deposit and letter of off-set; and • Guarantee by a director of the Company. Bank Loan Facility 1 is not a revolving credit facility that can be used for any purpose, with terms providing that the facility may only be drawn down by the Borrower for the following purposes: • "Accepted Bills-i", to facilitate local and export sales of the Borrower; • "Multi Currency Trade Financing-i", to facilitate local and export sales of the Borrower; and • "Bank Guarantee", for issuance of financial, performance and security bonds to government and private entities, in relation to business.		

Bank Loan Facility 2:

Parties: CIMB Islamic Bank Berhad (**Banker**), and Total Health Concepts Sdn Bhd (100% subsidiary of Holista Biotech Sdn Bhd) (**Borrower**).

i) Loan Facility 2

Term Loan

Principal Amount: MYR 200K / approximately A\$72K.

Amount Remaining as at 31 March 2026: MYR 70K / approximately A\$25K

Term: Commencing on 28 September 2022 and repayable over 60 monthly instalments (principal plus interest) of A\$1,420 (2025: A\$1,423) and ending in 44 months on 4 November 2027.

Interest Rate: 3.68% per annum (2025: 3.68%).

ii) Credit Standby Arrangement 2

Trade Financing and Banker Acceptance bears interest of 4.83% per annum (2025: 5.19%).

Total Amount at Quarter End: MYR 1.5M / Approximately A\$542K

Total Utilised at Quarter End: MYR 1.092K / Approximately A\$395K

Bank Loan Facility 2 is secured by the following:

- Fixed deposit with a licensed bank of the Group and the Company;
- Assignment of director insurance;
- Corporate guarantee; and
- Guarantee by a director of the Company.

Bank Loan Facility 2 is not a revolving credit facility that can be used for any purpose, with terms providing that the facility may only be drawn down by the Borrower for the following purposes:

- “**Accepted Bills-i**”, to facilitate local and export sales of the Borrower;
- “**Multi Currency Trade Financing-i**”, to facilitate local and export sales of the Borrower;
- “**Documentary Credit-i**”, to facilitate local and import purchases of the Borrower;
- “**Accepted Bills-i 2**”, to facilitate local and import purchases of the Borrower; and
- “**Multi Currency Trade Financing-i 2**”, to facilitate local and import purchases of the Borrower.

Bank Loan Facility 3:

Parties: CIMB Islamic Bank Berhad (**Banker**), and Total Health Concepts Sdn Bhd (100% subsidiary of Holista Biotech Sdn Bhd) (**Borrower**).

i) Credit Standby Arrangement 3

Trade Financing and Banker Acceptance bears interest of 5.09% per annum.

Total Amount at Quarter End: MYR 3.0M / Approximately A\$1,084K

Total Utilised at Quarter End: MYR245K / Approximately A\$88K

Bank Loan Facility 3 is secured by the following:

- Fixed deposit with a licensed bank of the Group and the Company.

Bank Loan Facility 3 is not a revolving credit facility that can be used for any purpose, with terms providing that the facility may only be drawn down by the Borrower for the following purposes:

- “**Accepted Bills-i**”, to facilitate local and export sales of the Borrower;
- “**Multi-Currency Trade Financing-i**”, to facilitate local and export sales of the Borrower;
- “**Documentary Credit-i**”, to facilitate local and import purchases of the Borrower;
- “**Accepted Bills-i 2**”, to facilitate local and import purchases of the Borrower; and
- “**Multi-Currency Trade Financing-i 2**”, to facilitate local and import purchases of the Borrower.

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(155)
8.2	Cash and cash equivalents at quarter end (item 4.6)	1,944
8.3	Unused finance facilities available at quarter end (item 7.5)	1,306
8.4	Total available funding (item 8.2 + item 8.3)	3,250
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	20.97
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>		
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer: N/A	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Answer: N/A	
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	Answer: N/A	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>		

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 28 April 2026

Authorised by: The Board
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.